June 17, 2019 10:06 AM EDTUpdated July 3, 10:11 AM
Deals
Cell/Gene Tx

Sanofi Gen­zyme deserts gene ther­a­py de­vel­op­er Voy­ager Ther­a­peu­tics

Natalie Grover

Reporter

While gene ther­a­py com­pa­nies re­joice as the sec­tor gains trac­tion with ap­provals and a flur­ry of M&A ac­tiv­i­ty, one play­er is feel­ing the heat …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

WuXi com­pa­nies may sell units im­pact­ed by Biose­cure — re­port

Biotech's third quar­ter was rel­a­tive­ly bright — with a few caveats

EMA re­views hair loss prod­ucts fol­low­ing con­cerns about sui­ci­dal thoughts

Af­ter $14B ex­it, Karuna co-founder finds next bet; Ex-Re­genxbio CEO Ken Mills heads to Tag­works

Sanofi sells rare dis­ease drug En­jay­mo to Recor­dati for $825M up­front

sponsored

3 Tiers for AAV Po­ten­cy As­say De­vel­op­ment Suc­cess

A service from the Financial Times